Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ICUI 
ICU Medical Inc (ICUI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ICUI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 6.83% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.44B USD | Price to earnings Ratio - | 1Y Target Price 190 |
Price to earnings Ratio - | 1Y Target Price 190 | ||
Volume (30-day avg) 292564 | Beta 0.74 | 52 Weeks Range 93.36 - 196.26 | Updated Date 04/2/2025 |
52 Weeks Range 93.36 - 196.26 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.94% | Operating Margin (TTM) 7.31% |
Management Effectiveness
Return on Assets (TTM) 1.42% | Return on Equity (TTM) -5.76% |
Valuation
Trailing PE - | Forward PE 20.49 | Enterprise Value 4711814200 | Price to Sales(TTM) 1.45 |
Enterprise Value 4711814200 | Price to Sales(TTM) 1.45 | ||
Enterprise Value to Revenue 1.98 | Enterprise Value to EBITDA 18.12 | Shares Outstanding 24519000 | Shares Floating 22570965 |
Shares Outstanding 24519000 | Shares Floating 22570965 | ||
Percent Insiders 7.84 | Percent Institutions 99.94 |
Analyst Ratings
Rating 4 | Target Price 203.4 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ICU Medical Inc
Company Overview
History and Background
ICU Medical, Inc. was founded in 1982. It started as a small, innovative company focused on developing and manufacturing IV therapy products. Over time, it grew through organic expansion and strategic acquisitions, becoming a global leader in infusion therapy and medication delivery systems.
Core Business Areas
- Infusion Systems: Provides a comprehensive portfolio of infusion pumps, dedicated sets and accessories, and software for medication and fluid delivery.
- Medication Delivery: Offers IV solutions, sterile connectors, and hazardous drug handling solutions designed to improve medication safety and efficiency.
- IV Solutions: Includes a variety of IV solutions, premixes and nutrition products.
Leadership and Structure
ICU Medical is led by a board of directors and a management team headed by the CEO. The company has a functional organizational structure with departments such as R&D, Manufacturing, Sales & Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- Infusion Pumps and Sets: These products are used for precise delivery of fluids and medications to patients. ICU Medical competes with Becton Dickinson (BDX) and Baxter (BAX). It is difficult to get exact market share but ICU is a major player in the infusion market. Revenues from this product are substantial, being a primary driver of company sales.
- IV Solutions: These solutions provide necessary hydration, electrolytes, and nutrients to patients. Competitors include Baxter (BAX) and Fresenius Kabi. Revenue is significant. It is difficult to get exact market share but ICU is a major player in the IV solutions market.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory oversight, and competitive pressure. Growth is driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology.
Positioning
ICU Medical is a leading provider of infusion therapy and medication delivery solutions. Its competitive advantages include a broad product portfolio, a strong customer base, and a focus on innovation and patient safety.
Total Addressable Market (TAM)
The global infusion therapy market is estimated to be worth tens of billions of dollars. ICU Medical is well-positioned to capture a significant share of this market through its comprehensive product offerings and global presence.
Upturn SWOT Analysis
Strengths
- Broad Product Portfolio
- Strong Customer Relationships
- Focus on Innovation
- Global Presence
- Strong Balance Sheet
Weaknesses
- Dependence on Hospital Spending
- Product Recalls
- Integration risks with large acquisitions
Opportunities
- Expanding into Emerging Markets
- Developing New Technologies
- Acquiring Complementary Businesses
- Increasing demand for home infusion therapy
Threats
- Intense Competition
- Regulatory Changes
- Economic Downturns
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- BDX
- BAX
- PKI
Competitive Landscape
ICU Medical competes with larger, more established companies. It differentiates itself through innovation and a focus on specialized markets.
Major Acquisitions
Smiths Medical
- Year: 2022
- Acquisition Price (USD millions): 2350
- Strategic Rationale: Expanded ICU Medical's product portfolio and geographic reach.
Growth Trajectory and Initiatives
Historical Growth: ICU Medical has grown through organic expansion and acquisitions. Growth rates have varied over time.
Future Projections: Analyst estimates vary. Growth projections are subject to change based on market conditions and company performance.
Recent Initiatives: Recent initiatives might include new product launches, strategic partnerships, or acquisitions.
Summary
ICU Medical is a prominent player in the infusion therapy and medication delivery space, marked by strategic acquisitions and a broad product portfolio. Its strengths lie in its global presence and innovative focus. However, dependence on hospital spending and integration risks remain potential concerns. Overall, ICU Medical shows reasonable financial health within a competitive landscape.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BAX
Baxter International Inc
BAX
Baxter International Inc
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
VTRS
Viatris Inc
VTRS
Viatris Inc
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Industry Analysis Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICU Medical Inc
Exchange NASDAQ | Headquaters San Clemente, CA, United States | ||
IPO Launch date 1992-03-31 | CEO & Chairman of the Board Mr. Vivek Jain | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15000 | Website https://www.icumed.com |
Full time employees 15000 | Website https://www.icumed.com | ||
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.